1
|
Vázquez A, Simó M, Persiva O, Sánchez L, Sansano I, Alemán C. Diagnosis and outcome of patients with idiopathic pleural effusions. Rev Clin Esp 2023; 223:320-324. [PMID: 36990383 DOI: 10.1016/j.rceng.2023.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/11/2023]
Abstract
INTRODUCTION Long-term follow-up course for patients with idiopathic pleural effusions has not been established. METHODS From October 2013 to June 2021 all patients with idiopathic effusion were prospectively followed up with clinical examination and imaging at 1, 3, 6 and every 6 months for a minimum of 1 year. RESULTS Twenty-nine patients were diagnosed with idiopathic effusion and followed up. Mesothelioma was detected during the follow-up in two patients at 7 and 18 months, one of whom had blood-tinged pleural fluid and the other reported a 10% weight loss. Mesothelioma was not diagnosed in any of the patients with effusion covering less than two thirds of the hemithorax, and without constitutional symptoms or a blood-tinged fluid appearance. Most of the effusions resolved or showed a clear improvement in the first six months. CONCLUSION Patients without weight loss and with small, non-hematic effusions, may benefit from conservative treatment and clinical-radiological follow-up.
Collapse
Affiliation(s)
- A Vázquez
- Departments of Internal Medicine, University Autonomous of Barcelona, Universitat Autònoma de Barcelona, University Hospital Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain
| | - M Simó
- Departments of Nuclear Imaging, University Autonomous of Barcelona, Universitat Autònoma de Barcelona, University Hospital Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain
| | - O Persiva
- Departments of Radiology, University Autonomous of Barcelona, Universitat Autònoma de Barcelona, University Hospital Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain
| | - L Sánchez
- Departments of Thoracic Surgery, University Autonomous of Barcelona, Universitat Autònoma de Barcelona. University Hospital Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain
| | - I Sansano
- Departments of Pathology, University Autonomous of Barcelona, Universitat Autònoma de Barcelona, University Hospital Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain
| | - C Alemán
- Departments of Internal Medicine, University Autonomous of Barcelona, Universitat Autònoma de Barcelona, University Hospital Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
| |
Collapse
|
2
|
Hernandez S, Rodriguez Carrillo J, Caminoa A, Benito A, Martinez R, Alonso M, Clave S, Arriola E, Esteban-Rodriguez I, De Castro J, Sansano I, Felip E, Abdulkader I, Garcia J, Rojo F, Domine M, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, Lopez-Vilaro L, Majem M, Garrido P, Paz-Ares L, Lopez-Rios F, Conde E. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
3
|
Conde E, Hernandez S, Caminoa A, Benito A, Martinez R, Alonso M, Jimenez B, Boni V, Remon J, Pijuan L, Clave S, Arriola E, Esteban I, De Castro J, Sansano I, Felip E, Abdulkader I, Garcia J, Rojo F, Domine M, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, Lopez-Vilaro L, Majem M, Enguita A, Paz-Ares L, Garrido P, Lopez-Rios F. MA14.02 RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
Cedrés S, Ponce-Aix S, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Gómez-Abecia S, Zucchiatti AC, Sansano I, Enguita AB, Miquel JM, Viaplana C, Dienstmann R, Paz-Ares L, Felip E. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. Clin Transl Oncol 2020; 22:1390-1398. [PMID: 31916017 DOI: 10.1007/s12094-019-02275-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2019] [Accepted: 12/16/2019] [Indexed: 01/13/2023]
Abstract
BACKGROUND Promising results have been reported with immune checkpoint inhibitors (ICI) in a small proportion of MPM patients. MMR deficiency (dMMR) has been well described in several malignancies and was approved as a biomarker for anti-PD-1 inhibitors. Next generation sequencing (NGS) data demonstrated that 2% of MPM harbor microsatellite instability. The aim of this study is to characterize MMR by immunohistochemistry (IHC) in a series of MPM including a subset of patients treated with immunotherapy. METHODS Tumors of 159 MPM p diagnosed between 2002 and 2017 were reviewed. Formalin-fixed, paraffin-embedded tissue was stained for MLH1, MSH2, MSH6 and PMS2 and tumors were classified as dMMR (MMR protein expression negative) and MMR intact (all MMR proteins positively expressed). We retrospectively collected clinical outcomes under standard chemotherapy and experimental immunotherapy in the entire cohort. RESULTS MMR protein expression was analyzed in 158 samples with enough tissue and was positive in all of the cases. Twenty two patients received ICI with anti-CTLA4 or anti-PD-1 blockade in clinical trials, 58% had a response or stable disease for more than 6 m, with median progression-free survival (PFS) of 5.7 m (2.1-26.1 m). The median overall survival (mOS) in all population was 15 months (m) (13.5-18.8 m). In a multivariable model factors associated to improved mOS were PS 0, neutrophil-lymphocyte ratio (NLR) < 5 and epithelioid histology (p < 0.001). CONCLUSIONS In our series we were unable to identify any MPM patient with dMMR by IHC. Further studies are needed to elucidate potential predictive biomarkers of ICI benefit in MPM.
Collapse
Affiliation(s)
- S Cedrés
- Medical Oncology Department, Vall d´Hebron University Hospital and Institute of Oncology, Barcelona, Spain.
- Servicio de Oncología, Hospital Vall D´Hebron, Paseo Vall d´Hebron 119-129, 08035, Barcelona, Spain.
| | - S Ponce-Aix
- CIBERONC, Madrid, Spain
- Medical Oncology Department, University Hospital Doce de Octubre, Madrid, Spain
| | - P Iranzo
- Medical Oncology Department, Vall d´Hebron University Hospital and Institute of Oncology, Barcelona, Spain
| | - A Callejo
- Medical Oncology Department, Vall d´Hebron University Hospital and Institute of Oncology, Barcelona, Spain
| | - N Pardo
- Medical Oncology Department, Vall d´Hebron University Hospital and Institute of Oncology, Barcelona, Spain
| | - A Navarro
- Medical Oncology Department, Vall d´Hebron University Hospital and Institute of Oncology, Barcelona, Spain
| | - A Martinez-Marti
- Medical Oncology Department, Vall d´Hebron University Hospital and Institute of Oncology, Barcelona, Spain
| | | | - A C Zucchiatti
- Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain
| | - I Sansano
- Pathological Anatomy Department, University Hospital Doce de Octubre, Madrid, Spain
| | - A B Enguita
- Pathological Anatomy Department, University Hospital Doce de Octubre, Madrid, Spain
| | - J M Miquel
- Vall d´Hebron Institute of Oncology, Barcelona, Spain
| | - C Viaplana
- Oncology Data Science (ODysSey) Group, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - R Dienstmann
- Medical Oncology Department, Vall d´Hebron University Hospital and Institute of Oncology, Barcelona, Spain
- Oncology Data Science (ODysSey) Group, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - L Paz-Ares
- CIBERONC, Madrid, Spain
- H12O-CNIO Lung Cancer Clinical Research Unit, Biomedical Research Foundation I+12, Madrid, Spain
- H12O-CNIO Lung Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
- Medical School, Complutense University, Madrid, Spain
| | - E Felip
- Medical Oncology Department, Vall d´Hebron University Hospital and Institute of Oncology, Barcelona, Spain
| |
Collapse
|
5
|
Gonçalves-Ferri WA, Jauregui A, Martins-Celini FP, Sansano I, Fabro AT, Sacramento EMF, Aragon DC, Ochoa JM. Analysis of different levels of positive end-expiratory pressure during lung retrieval for transplantation: an experimental study. ACTA ACUST UNITED AC 2019; 52:e8585. [PMID: 31314854 PMCID: PMC6644527 DOI: 10.1590/1414-431x20198585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Accepted: 04/24/2019] [Indexed: 11/22/2022]
Abstract
Atelectasis and inadequate oxygenation in lung donors is a common problem during the retrieval of these organs. Nevertheless, the use of high positive end-expiratory pressure (PEEP) is not habitual during procedures of lung retrieval. Twenty-one Sprague-Dawley male consanguineous rats were used in the study. The animals were divided into 3 groups according to the level of PEEP used: low (2 cmH2O), moderate (5 cmH2O), and high (10 cmH2O). Animals were ventilated with a tidal volume of 6 mL/kg. Before lung removal, the lungs were inspected for the presence of atelectasis. When atelectasis was detected, alveolar recruitment maneuvers were performed. Blood gasometric analysis was performed immediately. Finally, the lungs were retrieved, weighed, and submitted to histological analysis. The animals submitted to higher PEEP showed higher levels of oxygenation with the same tidal volumes PO2=262.14 (PEEP 2), 382.4 (PEEP 5), and 477.0 (PEEP 10). The occurrence of atelectasis was rare in animals with a PEEP of 10 cmH2O, which therefore required less frequent recruitment maneuvers (need for recruitment: PEEP 2=100%, PEEP 5 =100%, and PEEP 10=14.3%). There was no change in hemodynamic stability, occurrence of pulmonary edema, or other histological injuries with the use of high PEEP. The use of high PEEP (10 cmH2O) was feasible and probably a beneficial strategy for the prevention of atelectasis and the optimization of oxygenation during lung retrieval. Clinical studies should be performed to confirm this hypothesis.
Collapse
Affiliation(s)
- W A Gonçalves-Ferri
- Departamento de Pediatria, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - A Jauregui
- Department of Thoracic Surgery, Hospital Vall d'Hebron, Barcelona, Spain
| | - F P Martins-Celini
- Departamento de Pediatria, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - I Sansano
- Department of Pathology, Hospital Vall d'Hebron, Barcelona, Spain
| | - A T Fabro
- Departamento de Patologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - E M F Sacramento
- Departamento de Pediatria, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - D C Aragon
- Departamento de Pediatria, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - J M Ochoa
- Department of Thoracic Surgery, Hospital Vall d'Hebron, Barcelona, Spain
| |
Collapse
|
6
|
Van Seijen M, Brcic L, Navarro A, Sansano I, Béndek M, Witte B, Brcic I, Kammler R, Stahel R, Thunnissen E. 21P Influence of delayed and prolonged fixation on the evaluation of immunohistochemical staining on pulmonary resection specimen. J Thorac Oncol 2018. [DOI: 10.1016/s1556-0864(18)30301-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Remon J, Martinez-Marti A, Carcereny Costa E, Zeron-Medina Cuairan J, Sansano I, Mate J, Pardo N, Cedres S, Navarro A, Martinez de castro A, Moran T, Felip Font E. Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx381.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Varona Porres D, Persiva Ó, Pallisa E, Sansano I. Diagnostic imaging in spontaneous rupture of a thoracic duct cyst in the mediastinum. Radiologia 2016; 58:491-495. [PMID: 27117300 DOI: 10.1016/j.rx.2016.03.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Revised: 03/10/2016] [Accepted: 03/13/2016] [Indexed: 11/26/2022]
Abstract
Thoracic duct cysts in the mediastinum are extremely rare; they can give rise to chylothorax when they spontaneously rupture or after they are operated on. We present the case of an adult woman with a thoracic duct cyst in the mediastinum and chylothorax from its spontaneous rupture; to our knowledge, this phenomenon has not been specifically reported before. We describe the clinical and radiological findings, the therapeutic management, and the pathology findings, reviewing the literature for this entity.
Collapse
Affiliation(s)
- D Varona Porres
- Departamento de Radiodiagnóstico, Hospital Vall d'Hebron, Barcelona, España.
| | - Ó Persiva
- Departamento de Radiodiagnóstico, Hospital Vall d'Hebron, Barcelona, España
| | - E Pallisa
- Departamento de Radiodiagnóstico, Hospital Vall d'Hebron, Barcelona, España
| | - I Sansano
- Departamento de Anatomía Patológica, Hospital Vall d'Hebron, Barcelona, España
| |
Collapse
|
9
|
Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, Sansano I, Montoro MA, Enguita A, Felip E. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Lung Cancer 2016; 96:1-6. [PMID: 27133741 DOI: 10.1016/j.lungcan.2016.03.001] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2015] [Revised: 02/24/2016] [Accepted: 03/07/2016] [Indexed: 11/19/2022]
Abstract
BACKGROUND Malignant pleural mesothelioma (MPM) frequently express elevated AKT/mTOR activity. Previous reports in gliomas, colon, breast and prostate cancer suggest that PTEN/PI3K pathway may be important for the induction of PD-L1 expression. This study explored the expression of PTEN/PI3K pathway and PD-L1 in MPM and its relationship with the patient́s prognosis MATERIAL AND METHODS Twenty seven consecutive MPM patients were reviewed. Formalin-fixed, paraffin-embedded tissue biopsies were used for immunohistochemical analysis of PTEN/PI3K pathway and PD-L1 RESULTS: Expression of PTEN, mTOR, pAKT, p4EBP1, peif4E, pS6 and FOXO3a was found in 88.5%, 92.3%, 78.3%, 38.5%, 100%, 52.2% and 100% of tumors and PD-L1 in 23%. We found a significant correlation between pAKT, FOXO3a and PD-L1 expression and longer overall survival (p <0.05). We did not identify significant association between the level of PD-L1 expression and alterations in PI3K pathway CONCLUSIONS This study shows PTEN/PI3K pathway and PD-L1 in MPM are frequently activated. Our results suggests that there is not association between PD-L1 and the involvement of the PI3K pathway in MPM.
Collapse
Affiliation(s)
- S Cedrés
- Medical Oncology Service, Vall d́Hebron Institute Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Universidad Autonoma de Barcelona, Barcelona, Spain.
| | - S Ponce-Aix
- Medical Oncology Service, 12 de Octubre University Hospital, Madrid, Spain
| | - N Pardo-Aranda
- Medical Oncology Service, Vall d́Hebron Institute Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Universidad Autonoma de Barcelona, Barcelona, Spain
| | - A Navarro-Mendivil
- Medical Oncology Service, Vall d́Hebron Institute Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Universidad Autonoma de Barcelona, Barcelona, Spain
| | - A Martinez-Marti
- Medical Oncology Service, Vall d́Hebron Institute Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Universidad Autonoma de Barcelona, Barcelona, Spain
| | - J Zugazagoitia
- Medical Oncology Service, 12 de Octubre University Hospital, Madrid, Spain
| | - I Sansano
- Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain
| | - M A Montoro
- Pathology Department, Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - A Enguita
- Pathology Department, 12 de Octubre University Hospital, Madrid, Spain
| | - E Felip
- Medical Oncology Service, Vall d́Hebron Institute Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Universidad Autonoma de Barcelona, Barcelona, Spain
| |
Collapse
|
10
|
Cedres S, Ponce Aix S, Zugazagoitia J, Anguita A, Sansano I, Navarro Mendivil A, Martinez A, Martinez P, Fidalgo P, Felip E. Analysis of Expression of Programmed Cell Death 1 Ligand 1 (Pd-L1) in Malignant Pleural Mesothelioma (Mpm). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu438.66] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Peg V, Espinosa-Bravo M, Vieites B, Vilardell F, Antúnez JR, de Salas Sancho M, Sansano I, Delgado SJJ, Pinto W, Gozalbo F, Petit A, Rubio I. Abstract P1-01-29: Intraoperative molecular analysis of sentinel lymph node as a new predictor of axillary status in early breast cancer patients. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-01-29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The one-step nucleic acid amplification (OSNA) assay (Sysmex Corporation, Kobe, Japan) is a new diagnostic device that uses molecular biological techniques to analyze sentinel lymph node (SLN). Intraoperative SLN assessed by OSNA has been validated as an accurate method for detection of SLN metastasis compared to conventional histological examination. Although recent reports have shown that breast cancer patients with <2 positive SLNs can be spared of a complete axillary lymph node dissection (cALND), there are still a number of patients for whom prediction of non SLN metastasis may be helpful for cALND decision making.
The aim of the present study is to assess the intraoperative positive SLN total tumor load (TTL, defined as the amount of CK19 mRNA copies [copies/μL] in all positive SLNs) obtained by OSNA and to determine whether it is predictive of non-SLNs metastasis independently of the number of affected SLN and the type of surgery.
Data were collected during the month of June 2012 from medical records and include age, tumor size and grade, estrogen and progesterone receptor status, HER2 status, Ki67, presence of lymphovascular invasion (LVI), total number of SLN and non-SLN, number of positive and negative non-SLN, size of SLN and non-SLN metastasis, and TTL in each SLN. A total number of 701 patients were recruited, of which 697 (99,4%) met the study selection criteria. Univariate logistic regression showed that, in addition to TTL (p < 0,001), the number of affected SLNs (p < 0,001), tumor size (p < 0,001), HER2 status (p = 0,007), and LVI (p < 0,001) were predictive of ALND status. The multivariate logistic regression analysis showed that TTL is an independent predictor of metastatic non-SLNs, after adjusting for the tumor size, HER2 status, LVI and, in particular, the number of affected SLNs.
Moreover, the ROC curve analysis showed that, as compared to the number of affected SLN, TTL has a better ROC curve, as measured by the AUC: LogTTL 0.709 (95% CI, 0.667–0.760); number of affected SLN 0.610 (95% CI, 0.570–0.652), p < 0.001. Furthermore, in patients possessing a TTL<15000, the frequency of non-SLN metastasis was 14,7% (NPV = 85,3%, PPV = 41,1%, Sensitivity = 76,7%, Specificity = 55,2%). Taking this value as a cutpoint, 85 patients with mastectomy may have spared a cALND considering the predictive results of the TTL. In seven patients with > 3 positive SLN the TTL was < 15000 so this group, even with 3 positive SLNs, have 14.7% of having additional non SLN metastasis.
In conclusion, TTL by OSNA is a newly standardized, automated, and reproducible tool that predicts axillary node status better and independently of the number of affected SLNs and the type of surgery. This value can then help clinicians to personalize surgical treatment. Prospective studies will be carried out to determine the clinical impact of this variable in the management of patients.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-01-29.
Collapse
Affiliation(s)
- V Peg
- Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| | - M Espinosa-Bravo
- Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| | - B Vieites
- Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| | - F Vilardell
- Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| | - JR Antúnez
- Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| | - M de Salas Sancho
- Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| | - I Sansano
- Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| | - Sánchez JJ Delgado
- Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| | - W Pinto
- Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| | - F Gozalbo
- Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| | - A Petit
- Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| | - I Rubio
- Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| |
Collapse
|
12
|
Elaraj D, Sippel R, Lindsay S, Sansano I, Duh Q, Clark O, Kebebew E. 11. Prospective Validation of a Simple Scoring Model to Predict Single Gland Disease in Patients With Primary Hyperparathyroidism (PHPT). J Surg Res 2009. [DOI: 10.1016/j.jss.2008.11.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|